Have Insiders Sold SinoMab BioScience Shares Recently?
Have Insiders Sold SinoMab BioScience Shares Recently?
Some SinoMab BioScience Limited (HKG:3681) shareholders may be a little concerned to see that the President of China & Executive Director, Shanchun Wang, recently sold a substantial HK$4.3m worth of stock at a price of HK$1.80 per share. That sale reduced their total holding by 16% which is hardly insignificant, but far from the worst we've seen.
一些中国三替生物科技有限公司(HKG:3681)的股东可能会有些担忧,因为中国董事长兼执行董事王善春最近以每股1.80港币的价格大举出售了价值430万港币的股票。 这笔交易使他们的总持股减少了16%,这并不算微不足道,但远非我们所见过的最糟糕的情况。
The Last 12 Months Of Insider Transactions At SinoMab BioScience
在中国三替生物科技公司的董事交易中,过去12个月中的内部交易情况
Notably, that recent sale by Shanchun Wang is the biggest insider sale of SinoMab BioScience shares that we've seen in the last year. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of HK$1.25. So it may not shed much light on insider confidence at current levels.
值得注意的是,王善春最近的交易是我们在过去一年中看到的中国三替生物科技公司股票内部人最大的卖出交易。虽然内部人卖出股票是一个负面因素,但对我们来说,如果股票以较低价格出售则更为负面。好消息是,这笔大宗交易的价格远高于当前的1.25港币。因此,这可能并未对目前水平的内部人信心产生太大影响。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以在下面的图表中查看过去一年(由公司和个人)的内部交易。通过单击下面的图表,您可以查看每个内部交易的详细信息!
I will like SinoMab BioScience better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到一些大规模的内幕买单,我会更喜欢SinoMab BioScience。在等待的同时,可以查看这个包含有被低估和小盘股票的免费名单,这些股票最近有大量内部买盘。
Insider Ownership Of SinoMab BioScience
SinoMab BioScience的内部持股
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that SinoMab BioScience insiders own 32% of the company, worth about HK$443m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
许多投资者喜欢查看公司内部持股比例。如果内部人拥有大量股份,这往往是一个好迹象。据透露,SinoMab BioScience内部人持有公司的32%股份,价值约为HK$44300万。这种程度的内部持股率很好,但并不是特别突出。它确实表明了一个合理的一致性程度。
What Might The Insider Transactions At SinoMab BioScience Tell Us?
SinoMab BioScience的内部交易可能给我们带来什么启示?
An insider sold SinoMab BioScience shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 5 warning signs (3 make us uncomfortable!) that you ought to be aware of before buying any shares in SinoMab BioScience.
最近有内部人卖出了SinoMab BioScience的股票,但他们没有进行买盘。从过去十二个月来看,我们的数据没有显示任何内部买盘。公司拥有较高的内部持股比例,但是考虑到过去的股票销售历史,我们还是有些犹豫。所以,虽然了解内部人在买卖方面的行动非常有帮助,但也了解公司面临的风险非常重要。为了帮助您了解这一点,我们已经发现了5个警告信号(其中3个让我们感到不舒服!),在购买SinoMab BioScience的任何股票之前您应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,您可能会在其他地方找到一项出色的投资。因此,请查看此免费的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。